Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db8acd71f5994544bda6df3f27a3f51e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 |
filingDate |
2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69756ae34bd8005b7d3e2c064e6e4f8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c76beaa1860d29d43ebd6df43070c36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c6306bc2aa6128b874b3a1be055dcd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8606762d0177390a6b18fbdad1f643f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f009e0b7878d80816e37fe78a2d06269 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de9980de8ad50451417aaca233d5d02 |
publicationDate |
2019-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3515483-A2 |
titleOfInvention |
Hepatitis c virus immunogenic compositions and methods of use thereof |
abstract |
The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient. |
priorityDate |
2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |